Roche would get PACB at discount price......
Next week will be very interesting for PACB:
"More Than 80 Presentations and Posters Feature PacBio SMRT Sequencing to Decipher Complex Plant and Animal Genomes at PAG "
Fiscal 2016 Second Quarter Results
Fiscal 2016 Second Quarter Results:
"For the three months ending September 30, 2015, Lucas reported a fiscal second quarter net loss of $1.0 million, or ($0.66) per common share, which was a 36% improvement over the $1.5 million net loss, or ($1.11) per share, for the same three month period last year. This improvement reflected a decrease in total operating expenses of approximately $0.9 million, partially offset by a decline of approximately $0.7 million in sales revenues. The loss per share in both quarters has been adjusted for our 1-for-25 reverse stock split which was effected on July 15, 2015, which reduced the number of our outstanding common shares from 36,354,973 to 1,454,261.
Total revenues from crude oil and natural gas sales for the quarter ended September 30, 2015 decreased by 70.8% to $0.3 million compared to $1.0 million for the same period a year ago and fell 26.4% sequentially from the fiscal first quarter. The year-over-year decline was primarily impacted by a $0.54 million drop in realized crude oil prices and a $0.16 million decrease related to a decline in quarterly production volumes. Production volumes averaged 72 net barrels of oil equivalent (BOE) per day during the three months ended September 30, 2015 compared to 113 net BOE per day during the three months ended September 30, 2014. The production decline can be attributed to workover drilling and lateral programs with higher front-end production in last year's fiscal second quarter coupled with production declines primarily related to interference from offset activity in the current period."